Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study Meeting Abstract
| Authors: | Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla, T.; Xie, F.; Metges, J. P.; Jieer, Y.; Bridgewater, J. A.; Tejani, M. A.; Chen, E. Y. S.; Wasan, H. S.; Ducreux, M. P.; Zhao, I.; Garfin, P. M.; Harding, J. J. |
| Abstract Title: | Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401063 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4091 |
| Notes: | Meeting Abstract: 4091 -- Source: Wos |
